CRITICAL SAFETY WARNING
Adipotide has documented dose-dependent kidney tubular toxicity in primate studies. No human therapeutic window has been established. Kidney function monitoring (creatinine, BUN, GFR) is non-negotiable for any use. This is the most risk-fraught compound in this guide.
What is Adipotide (FTPP)?
Adipotide (FTPP) is one of the most pharmacologically novel — and most risk-fraught — compounds in the biohacker space. The mechanism is unlike anything else: it's a chimeric peptide with two distinct functional domains. The first domain (CKGGRAKDC) home-targets the peptide to receptors on blood vessels specifically inside white adipose tissue (fat). The second domain (D(KLAKLAK)₂) is a mitochondria-disrupting sequence that kills cells when internalized. Together: the peptide seeks out fat vasculature, binds, enters the vascular endothelial cells, disrupts their mitochondria, kills them — and the fat cells die from loss of blood supply. The fat physically disappears.
The primate results are extraordinary: obese rhesus monkeys treated with Adipotide lost an average of 39% of body weight over 4 weeks. MRI confirmed the fat was gone, not redistributed. Insulin sensitivity improved dramatically. These results generated enormous excitement when published.
The problem — and it is serious — is renal toxicity. The same primate studies documented dose-dependent kidney tubular cell damage: proximal tubular necrosis, elevated creatinine, decreased kidney function. At doses required for dramatic fat loss, meaningful kidney damage occurred. Researchers could not establish a therapeutic window sufficient to justify human clinical trials. Development effectively stopped. The biohacker community uses Adipotide despite these concerns — anyone doing so without kidney function monitoring is taking a risk that cannot be adequately quantified.
How it works
Targeted Fat Vasculature Binding
The CKGGRAKDC domain of Adipotide binds specifically to prohibitin on the surface of endothelial cells lining blood vessels inside white adipose tissue (WAT). Prohibitin is overexpressed on WAT vasculature compared to other tissues — this overexpression creates the targeting selectivity. After binding, the peptide is internalized by the endothelial cells.
Mitochondrial Disruption and Fat Cell Death
Once internalized, the D(KLAKLAK)₂ domain disrupts mitochondrial membranes in the endothelial cells, causing mitochondrial swelling, cytochrome c release, and apoptosis. The vascular endothelial cells of fat tissue die. Fat cells, deprived of blood supply (ischemia), undergo apoptosis and subsequent phagocytosis. The fat physically disappears.
Why the Kidney Gets Hit
Prohibitin is expressed in kidney proximal tubular cells as well as fat vasculature — it is not perfectly selective for fat. At doses required for significant fat loss, Adipotide accumulates in kidneys as well, causing proximal tubular cell death (tubular necrosis). This is the same type of kidney damage seen with nephrotoxic drugs and contrast agents. The renal toxicity is a consequence of imperfect targeting specificity — not a side effect of the killing domain alone.
What the research shows
Adipotide drives fat loss with reversible renal effects in obese primates
Barnhart KF et al.
Obese rhesus monkeys given adipotide (0.43 mg/kg daily) lost about 10.6% of body weight, with reduced BMI and waist circumference and significantly improved insulin measures over the treatment period. Kidney effects were dose-dependent (rising creatinine, mild tubular changes) but reversed after stopping — the study that showed real efficacy alongside the renal signal that shaped its development.
View on PubMed →Proapoptotic peptide approach to targeting fat vasculature — mechanism
Kolonin MG et al.
Original paper establishing the prohibitin-targeting approach for fat vasculature elimination. Demonstrated selective targeting and fat reduction in rodent models. Foundational mechanism paper.
View on PubMed →What the community reports
Common misconceptions
"39% weight loss means this is the most effective fat-loss compound."
39% fat loss with dose-dependent kidney toxicity is not a viable therapeutic. The efficacy is remarkable; the toxicity at effective doses has no known mitigation. A compound that damages kidneys while burning fat is not a viable option without an established safe dose.
"Lower doses eliminate the kidney risk."
The primate data shows dose-dependent nephrotoxicity — lower doses produce less kidney damage. Whether lower doses in humans produce meaningful fat loss without nephrotoxicity is unknown. There is no established human therapeutic window. Lower dose is not the same as established safety.
"The kidney toxicity was reversible in the monkeys."
The kidney damage was described as reversible at the doses studied. However: reversible in primates does not equal reversible in humans; without monitoring, users cannot detect damage before it progresses; repeat cycles may produce cumulative damage that is not reversible.
FAT LOSS CONTEXT — ESTABLISHED ALTERNATIVES
Adipotide: most potent fat loss data in any primate, zero human trials, kidney toxicity risk. Semaglutide: ~15% weight loss in humans, established safety profile, GLP-1 class. Tirzepatide: ~22% weight loss in humans, GIP/GLP-1 dual agonist. AOD-9604: targeted lipolysis without kidney toxicity — very different risk profile.
Open PepperLedger to track your Adipotide protocol →
Free to join. No credit card. Ask the Researcher about kidney monitoring and protocol design once you're in.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · terminated · NCT01262664Prohibitin-targeting peptide 1 (adipotide-class) in metastatic prostate cancer and obesity